Genmab — April 2019

[E_L]

this must be the maintenance study they announced last week, named AURIGA https://clinicaltrials.gov/ct2/show/NCT03901963?term=NCT03901963&rank=1

[E_L]

Some LYRA results posted on clinicaltrials https://clinicaltrials.gov/ct2/history/NCT02951819?A=18&B=19&C=merged

[iboge]

Hvorfor laver man ikke det omvendte forsøg: A Study of Daratumumab Plus Lenalidomide Versus Daratumumab Alone for at vise, at Lenalidomide ikke er nødvendig ?.

[E_L]

because they actually seem to work well together

[Tandfeen-2]

Grrr, så falder vi tilbage igen

[E_L]

JNJ is doubling the size in the BCMA CD3 DuoBody trial, as it adds SC arms.

[E_L]

"Participants will receive JNJ-64007957 subcutaneously (SC) starting at an IV dose and schedule that was deemed safe and cleared by the safety evaluation team (SET). "

[E_L]

sounds positive to me they are doing this and indicates they have not yet found major safety issues with IV and found a "safe dose"

[E_L]

i think they did something similar to this, earlier this year with the CD3 GPRC5D trial

[kkjoel]

A very good little piece of news: sc-arms on BCMAxCD3 study - tnx EL

[kkjoel]

They keep popping up... those small pieces of good news, don't they? Hard to keep pessimisticism!

[JKY_VH]

tak E L

[peter12]

AQR har reduceret til 1,88% dvs 0,11% ?

[peter12]

I går

[Doc4]

Her lidt om omkostninger for Dara kombier...RESULTS:
The estimated cost per patient for each triplet regimen was $13,890 (DARA/BOR/DEX), $22,231 (IXA/LEN/DEX), $24,322 (ELO/LEN/DEX), $26,410 (DARA/LEN/DEX), and $27,432 (CAR/LEN/DEX). Drug acquisition costs and treatment duration were the largest drivers of cost. https://www.ncbi.nlm.nih.gov/pubmed/30917078

[Doc4]

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retros.These real-life results revealed modest efficacy of single-agent daratumumab in advanced patients with RRMM in comparison with data from clinical trials. The overall response rate was 24%, including 5% very good partial response or better. After a median follow-up of 6.5 months, all patients experienced disease relapse. The median progression-free survival was 1.9 mo.

[Doc4]

https://www.ncbi.nlm.nih.gov/pubmed/30874850

[peter12]

"Most patients presented with high-risk characteristics", så det er vel ikke en normal gruppe ?

[Bulder]

Lidt ringere end Sirius. 24% ORR vs 29% og median PFS 1,9 md vs. 3,7 md. Median antal forudgående behandlinger 4 vs 5. Om patienterne iøvrigt er sammenlignelige ved jeg ikke. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext

[bibob]

Det er jo ikke kun Genmab. Markedet afventer nogle nøgletal i slut ugen. Faldet har ikke noget med hverken dårlige eller gode nyheder at gøre ift Genmab.